By: IPP Bureau
Last updated : August 27, 2024 2:43 pm
The grant is designated for the research and development of Pyronaridine
Mangalam Drugs & Organics Limited has been awarded a grant by The Medicines for Malaria Venture (MMV). The grant amounts to US$ 274,800 and is designated for the research and development of Pyronaridine.
The Medicines for Malaria Venture (MMV), headquartered in Geneva, Switzerland, is a non- profit organization committed to the development and support of innovative antimalarial therapies. MMV focuses on advancing new treatments for malaria and optimizing combination therapies. The pyronaridine-artesunate combination therapy, endorsed by MMV, leverages the synergistic effects of both drugs to enhance therapeutic efficacy in combating malaria.
The grant will support research and development efforts aimed at improving the technology and efficiency of pyronaridine production. With an estimated international market size to reach 50 million treatments in the next few years.
Mangalam Drugs & Organics Limited plans to commercialize this product by the end of 2024 which will position the company at the forefront of global anti-malaria API production and performances.